CASE STUDY

Bridging the path to CDx success

A pharmaceutical company approached us with their own assay developed on our DISCOVERY platform. We moved quickly to establish a Master Collaboration Agreement and tested their assay only to find out that it failed requirements for a companion diagnostic. We pivoted to develop both the formulation locked assay and IUO and started clinical trials within record time, keeping their programs on track.

 

Expanding access to cancer therapies

Since the global launch of the VENTANA PD-L1 (SP263) Assay as a companion test, it has become the #3 selling assay in our portfolio of over 250 antibodies, and this collaboration has grown into a franchise with multiple indications. We now are their strategic partner for IHC and remain engaged with them on  multiple early and late stage development programs.

Together, we’ve enabled significant access to personalized therapy for cancer patients.

 

 

2,129

pathologists in 98 countries trained on the assay

10

IUO indications

46

registration trials ongoing, and 30 completed